Cellectis S.A. - American Depositary Shares (CLLS)
Frequently Asked Questions About Cellectis S.A. - American Depositary Shares (CLLS)
Has Cellectis faced any challenges or setbacks?
Like many biotech companies, Cellectis has faced several challenges and setbacks, particularly relating to the complexities of clinical trials and regulatory approvals. Such challenges are common in the clinical development of new therapies, and the company is continuously working to address these hurdles through innovation and strategic partnerships to keep advancing its pipeline.
How can investors keep track of Cellectis' performance?
Investors can keep track of Cellectis' performance by following the company's updates through its official website, where it provides investor relations information, financial reports, and press releases. Additionally, monitoring its stock on Nasdaq (ticker symbol CLLS) and reviewing analysis from financial news outlets can give insights into the company's market performance and developments. Regular earnings calls also provide stakeholders with updates on clinical advancements and strategic initiatives.
How many employees does Cellectis have?
Cellectis employs a dedicated workforce comprised of scientists, researchers, and corporate professionals. As of the latest data, the company has around 140 employees who contribute to its diverse portfolio, from research and development to regulatory affairs and commercialization, although this number may vary as the company adapts to its evolving needs.
What are the key technologies utilized by Cellectis?
Cellectis primarily utilizes its proprietary TALEN® gene-editing technology, which allows for precise and targeted modifications of DNA in living cells. This technology enables the creation of engineered allogeneic CAR T cells, designed to treat various cancers. By prioritizing this innovative platform, Cellectis aims to overcome the limitations of traditional therapies.
What does Cellectis S.A. do?
Cellectis S.A. is a biotechnology company focused on developing innovative therapies for cancer using its proprietary gene-editing technologies, particularly its pioneering research in CAR T-cell immunotherapy. By leveraging its TALEN® gene-editing platform, Cellectis aims to enhance the ability of the immune system to combat tumors, offering new treatment options for patients with various types of cancers.
What is Cellectis’ vision for the future?
Cellectis envisions a future where gene-editing technologies are integrated into mainstream cancer treatment, providing personalized and effective therapies that cater to the specific needs of patients. The company forecasts expanding its pipeline of therapies and continuing to innovate in the areas of immunotherapy and genetic engineering, thereby reinforcing its leadership role in transforming oncology.
What is TALEN® technology used for?
TALEN® technology is utilized for gene editing, allowing researchers to make precise modifications to DNA sequences. Cellectis employs this technology in its development of engineered immune cells, particularly in CAR T-cell therapies aimed at treating cancer. This targeted approach facilitates the creation of therapies that can potentially improve patient outcomes through more effective immunological responses.
What is the company’s approach to sustainability?
Cellectis is committed to sustainable practices and aims to minimize its environmental impact throughout its operations. The company integrates sustainability into its research and development processes, promoting responsible use of resources and adherence to ethical standards in biotechnology, thereby aligning its operations with broader societal goals toward health and environmental stewardship.
What is the financial performance of Cellectis?
Cellectis' financial performance reflects its growth trajectory in the biotech sector, driven by investments in research and development as well as collaborations with external partners. The company is publicly traded on Nasdaq under the ticker symbol CLLS, and its financial metrics demonstrate a focus on innovation and long-term strategic growth, alongside the challenges inherent in the biotechnology landscape.
What is the mission of Cellectis?
Cellectis' mission is to develop safe and effective gene-editing therapies that fundamentally transform cancer care. The company aims to harness the immune system's power to recognize and fight tumors, with a strategic focus on making revolutionary advancements in the field of oncology. By prioritizing innovative research, Cellectis is committed to improving patient outcomes and bringing hope to those affected by cancer.
What is the regulatory status of Cellectis’ therapies?
Cellectis’ therapies are subject to strict regulatory scrutiny by agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). The company seeks regulatory approval through rigorous clinical trial processes to demonstrate the safety and efficacy of its products before they can be commercialized. The company closely monitors compliance and engages proactively with regulatory bodies to ensure the timely advancement of its therapies.
What is the significance of Cellectis in the gene-editing landscape?
Cellectis holds a significant position in the gene-editing landscape due to its pioneering work with its TALEN® technology, which was among the first to enable precise editing of genes in various types of cells. The company’s advancements have contributed to the broader field of gene-editing in therapeutics by providing safer and more effective methods for developing personalized medicine, especially in the area of cancer treatment.
What is the status of Cellectis’ clinical trials?
Cellectis is actively conducting several clinical trials to assess the efficacy and safety of its cancer therapies. The status of these trials varies, with some in early-phase studies while others are in later phases of development. The progress of these trials is crucial for determining the potential market availability of their products, and Cellectis regularly updates stakeholders on trial advancements.
What products has Cellectis developed?
Cellectis has developed several product candidates in its pipeline, including clinical-stage CAR T-cell therapies designed to treat various cancers such as acute lymphoblastic leukemia (ALL) and solid tumors. Each product candidate is derived from the company’s proprietary gene-editing technologies, representing a significant advancement in personalized cancer treatment solutions.
What types of cancer therapies is Cellectis developing?
Cellectis is developing a range of innovative cancer therapies, mainly focused on CAR T-cell therapies. These treatments are designed to harness the body’s immune system to target and destroy cancer cells. The company's research includes therapies for hematological cancers as well as solid tumors, contributing to a growing pipeline of potential therapeutics.
When was Cellectis founded?
Cellectis was founded in 1999. Since its inception, the company has grown substantially, expanding its focus on gene-editing technologies and becoming a leader in the biotechnology sector. Over the years, Cellectis has established a strong portfolio of patents and partnerships, positioning itself for continued innovation in cancer therapies.
Where is Cellectis S.A. headquartered?
Cellectis S.A. is headquartered in Paris, France. The company operates with a global focus, conducting its research and development efforts, including clinical studies, in various locations around the world. The Paris headquarters serves as the central hub for its strategic and operational decisions.
Who are some of Cellectis’ partners or collaborators?
Cellectis has formed strategic partnerships and collaborations with various academic institutions and pharmaceutical companies to enhance its research and development efforts. Notable partnerships include collaborations with leading healthcare organizations such as Pfizer and Servier, allowing Cellectis to leverage shared expertise and resources in oncology and gene therapy.
What is the current price of Cellectis S.A. - American Depositary Shares?
The current price of Cellectis S.A. - American Depositary Shares is 1.160
When was Cellectis S.A. - American Depositary Shares last traded?
The last trade of Cellectis S.A. - American Depositary Shares was at 4:00 pm EDT on April 7th, 2025
What is the market capitalization of Cellectis S.A. - American Depositary Shares?
The market capitalization of Cellectis S.A. - American Depositary Shares is 52.76M
How many shares of Cellectis S.A. - American Depositary Shares are outstanding?
Cellectis S.A. - American Depositary Shares has 45.48M shares outstanding.